LJP 394 data

LJPC announced positive results from a dose-ranging Phase II study of LJP 394, which is designed to reduce levels of double-stranded DNA (dsDNA) antibodies. The antibodies are believed to be responsible for lupus nephritis, a major cause of morbidity and mortality in lupus patients.

The double blind, placebo controlled study in 58 patients with mild lupus tested varying doses and frequences of administration. Patients were evaluated for two months, treated for four months and monitored for two months after treatment. ...